Table 1.
List of antibody-drug conjugates investigated for multiple myeloma.
| Drug name | Target | Effector moiety | Development state | Clinical trial | Treatment regimen | Status | References |
|---|---|---|---|---|---|---|---|
| Belantamab mafodotin (GSK2857916) | BCMA (CD269) | Monomethyl auristatin F | Clinical | NCT02064387 (DREAMM-1); phase 1 | Bela mono | Completed | (13, 16–21) |
| NCT03525678 (DREAMM-2); phase 2 | Bela mono | Active, not recruiting | |||||
| NCT03715478 (DREAMM-3); phase 3 | Bela mono vs. pom + dex | Recruiting | |||||
| NCT03848845 (DREAMM-4); phase 1/2 | Bela + pembro | Recruiting | |||||
| NCT04126200 (DREAMM-5); phase 1/2 | Bela + innovative anti-cancer drugs | Recruiting | |||||
| NCT03544281 (DREAMM-6); phase 1/2 | Bela + len + dex or Bela + bort + dex | Recruiting | |||||
| NCT03715478 (ALGONQUIN); phase 1/2 | Bela + pom + dex | Recruiting | |||||
| (DREAMM-7); phase 3 | Bela + bort + dex vs. dara + bort + dex | Planned | |||||
| (DREAMM-8); phase 3 | Bela + pom + dex vs. bort + pom + dex | Planned | |||||
| NCT04091126 (DREAMM-9); phase 3 | Bela + bort + len + dex vs. bort + len + dex | Recruiting | |||||
| (DREAMM-10); phase 3 | Bela + novel agent vs. SOC | Planned | |||||
| MEDI2228 | BCMA (CD269) | Pyrrolo-benzodiazepine | Clinical | NCT03489525; phase 1 | MEDI2228 mono | Recruiting | (22–26) |
| HDP-101 | BCMA (CD269) | Amanitin | Preclinical | - | - | - | (27–30) |
| CC-99712 | BCMA (CD269) | Undisclosed | Clinical | NCT04036461; phase 1 | CC-99712 mono | Recruiting | - |
| AMG 224 | BCMA (CD269) | Maytansinoid DM1 | Clinical | NCT02561962; phase 1 | AMG 224 mono | Active, not recruiting | - |
| SG1-vcMMAF8 SG2-vcMMAF8 SG3-vcMMAF8 |
BCMA (CD269) | Monomethyl auristatin F | Preclinical | - | - | - | (31) |
| BCMA-024 BCMA-077 |
BCMA (CD269) | Duostatin 5.2 | Preclinical | - | - | - | (32) |
| CD38-077 | CD38 | Duostatin 5.2 | Preclinical | - | - | - | (33) |
| Dara-DM4 | CD38 | Maytansinoid DM4 |
Preclinical | - | - | - | (34) |
| FOR46 | CD46 | Monomethyl auristatin F | Clinical | NCT03650491; phase 1 | FOR46 mono | Recruiting | (35) |
| SGN-CD48A | CD48 | Monomethyl auristatin E | Clinical | NCT03379584; phase 1 | SGN-CD48A mono | Terminated (due to overall benefit/risk profile) | (36, 37) |
| Lorvotuzumab mertansine (IMGN901) | CD56 | Maytansinoid DM1 | Clinical |
NCT00346255; phase 1 NCT00991562; phase 1 NCT02420873; phase 2 |
Lorvo mono Lorvo + len + dex Lorvo mono |
Completed Completed Completed |
(12, 38–42) |
| STRO-001 | CD74 | DBCO-linker-maytansinoid (SC236) | Clinical | NCT03424603; phase 1 | STRO-001 mono | Recruiting | (43, 44) |
| Milatuzumab-doxorubicin (IMMU-110) | CD74 | Doxorubicin | Clinical | NCT01101594; phase 1/2 | Mila mono | Completed | (45) |
| Indatuximab ravtansine (BT062) | CD138 | Maytansinoid DM4 | Clinical |
NCT00723359; phase 1 NCT01001442; phase 1/2a NCT01638936; phase 1/2a |
Inda mono single-dose Inda mono multi-dose Inda + len + dex and inda + pom + dex |
Completed Completed Completed |
(46–50) |
| B-B4-DM1 | CD138 | Maytansinoid DM1 |
Preclinical | - | - | - | (51) |
| DFRF4539A | FcRL5 (CD307) | Monomethyl auristatin E | Clinical | NCT01432353; phase 1 | DFRF4539A mono | Completed | (52, 53) |
| Anti-FcRL5-SPDB-DM4 | FcRL5 (CD307) | Maytansinoid DM4 | Preclinical | - | - | - | (52) |
| Azintuxizumab vedotin (ABBV-838) | SLAMF7 (CD319) | Monomethyl auristatin E | Clinical |
NCT02951117; phase 1b NCT02462525; phase 1/1b |
Azin + venetoclax + dex Azin & azin + pom + dex |
Withdrawn Terminated (No Go decision) |
(54–56) |
| SGN-CD352A | SLAMF6 (CD352) | Pyrrolo-benzodiazepine | Clinical | NCT02954796; phase 1 | SGN-CD352A mono | Terminated (sponsor decision) | (57) |
| MEDI7247 | ASCT2 (SLC1A5) | Pyrrolo-benzodiazepine | Clinical | NCT03106428; phase 1 | MEDI7247 mono | Active, not recruiting | (58) |
| M24-DOX | Matriptase | Doxorubicin | Preclinical | - | - | - | (59) |
azin, azintuxizumab vedotin; bela, belantamab mafodotin; bort, bortezomib; dara, daratumumab; dex, dexamethasone; inda, indatuximab ravtansine; len, lenalidomide; lorvo, lorvotuzumab mertansine; mila, milatuzumab-doxorubicin; mono, monotherapy; pembro, pembrolizumab; pom, pomalidomide; SOC, standard-of-care; vs, versus.